Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs By Ogkologos - July 28, 2026 110 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMPETE study Source RELATED ARTICLESMORE FROM AUTHOR Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce MOST POPULAR Groundbreaking Physicist Uses Laser Technology To Kill Cancer Cells Without Any... June 9, 2020 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... May 29, 2020 Prognostic Role of ctDNA in Patients with Surgically Resectable Colorectal Cancer January 30, 2023 Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient... May 31, 2024 Load more HOT NEWS How to Make the Most of Your Patient Portal During Cancer EMA Recommends Granting a Marketing Authorisation for Camizestrant Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease... Increased Risk of Cancer in Early Life Among Individuals with Autism...
